Martek (MTK) Announces Settlement of Patent Dispute with Capsugel France
Martek Biosciences Corporation (Nasdaq: MATK) announced earlier it has resolved a patent dispute with Capsugel France. The resolution follows Martek's November 2008 action for infringement filed in the High Court of Strasbourg, France.
As a result of this settlement agreement between Martek and Capsugel France, Capsugel and all of its affiliates have agreed to purchase all of their algal DHA exclusively from Martek for the life of the patent in question. Additionally, Martek and Capsugel will develop a product containing Martek's algal DHA in Capsugel's proprietary Licaps(R) liquid-filled hard capsules.
As a result of this settlement agreement between Martek and Capsugel France, Capsugel and all of its affiliates have agreed to purchase all of their algal DHA exclusively from Martek for the life of the patent in question. Additionally, Martek and Capsugel will develop a product containing Martek's algal DHA in Capsugel's proprietary Licaps(R) liquid-filled hard capsules.
You May Also Be Interested In
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- JAKKS Pacific (JAKK) Announces 4M Common Tender at $20/Share
- BofA (BAC), Barclays (BCS) to Sell Remaining Archstone Interest in $1.58B Deal to Lehman Bros.
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
